Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence G Lum

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Clinical Prostate Cancer|October 14, 2004
Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige micePamela A Davol, Janelle A Smith, Nicola Kouttab, et al.
Journal of Translational Medicine|July 11, 2014
Ipilimumab augments antitumor activity of bispecific antibody-armed T cellsHiroshi Yano, Archana Thakur, Elyse N Tomaszewski, et al.
Experimental Hematology|March 23, 2005
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitroJonathan M Gall, Pamela A Davol, Ryan C Grabert, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot studyArchana Thakur, Peter Littrup, Elyse N Paul, et al.
Journal of Translational Medicine|December 16, 2014
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cellsKatarzyna Urbanska, Rachel C Lynn, Caitlin Stashwick, et al.
BMC Cancer|February 26, 2013
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodiesIan M Zitron, Archana Thakur, Oxana Norkina, et al.
Oncoimmunology|December 8, 2018
Immune T cells can transfer and boost anti-breast cancer immunityArchana Thakur, Ritesh Rathore, Sri Vidya Kondadasula, et al.
Blood Cells, Molecules & Diseases|February 6, 2004
Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardiumLawrence G Lum, Hubert Fok, Richard Sievers, et al.
Cancer|February 26, 2004
Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal modelLifen Ren-Heidenreich, Pamela A Davol, Nicola M Kouttab, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine releaseJeong A Park, Brian H Santich, Hong Xu, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Clinical Prostate Cancer|October 14, 2004
Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige micePamela A Davol, Janelle A Smith, Nicola Kouttab, et al.
Journal of Translational Medicine|July 11, 2014
Ipilimumab augments antitumor activity of bispecific antibody-armed T cellsHiroshi Yano, Archana Thakur, Elyse N Tomaszewski, et al.
Experimental Hematology|March 23, 2005
T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitroJonathan M Gall, Pamela A Davol, Ryan C Grabert, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 18, 2011
Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot studyArchana Thakur, Peter Littrup, Elyse N Paul, et al.
Journal of Translational Medicine|December 16, 2014
Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cellsKatarzyna Urbanska, Rachel C Lynn, Caitlin Stashwick, et al.
BMC Cancer|February 26, 2013
Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodiesIan M Zitron, Archana Thakur, Oxana Norkina, et al.
Oncoimmunology|December 8, 2018
Immune T cells can transfer and boost anti-breast cancer immunityArchana Thakur, Ritesh Rathore, Sri Vidya Kondadasula, et al.
Blood Cells, Molecules & Diseases|February 6, 2004
Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardiumLawrence G Lum, Hubert Fok, Richard Sievers, et al.
Cancer|February 26, 2004
Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal modelLifen Ren-Heidenreich, Pamela A Davol, Nicola M Kouttab, et al.
Journal for Immunotherapy of Cancer|May 14, 2021
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine releaseJeong A Park, Brian H Santich, Hong Xu, et al.
Pageof 9